Vaccinogen Information

Vaccinogen is a US-based biotechnology company formed in 2007 to complete the pivotal trial of a new vaccine for Stage II Colon Cancer, OncoVAX. Building on the basic research and early clinical trials done by Dr. Michael Hanna which culminated in a successful Phase III Trial, and now with a Fast-Track designation and Special Protocol Assessment from the FDA, Vaccinogen is focused on completing a Pivotal Phase IIIb Trial within four years of funding, and achieving FDA approval for OncoVAX by 2027. OncoVAX has been shown to reduce the recurrence of Stage II Colon Cancer from 1-in-3 in untreated patients, to 1-in-9 for those receiving the OncoVAX regimen.